Dexamethasone has a longer half-life than prednisone or prednisolone and tastes better in liquid form; therefore, substitution of dexamethasone for prednisone/prednisolone may result in better patient ...

E.S. (M.G.H. 876315), a 52-year-old woodsman with acrodermatitis continua (Hallopeau), was admitted to the Massachusetts General Hospital on November 8, 1954, because of a dermatosis involving the ...

— Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

THE treatment of acute leukemia of adults has been attended with considerable disappointment. The folic acid antagonists, although occasionally productive of well defined remissions, ordinarily have ...

You are working a moderately busy evening shift in the pediatric ED. The medical student has just finished presenting the kid he saw in bed eight. The patient is an 8-year-old boy with known asthma, ...

Please provide your email address to receive an email when new articles are posted on . Prolonged initial prednisolone therapy does not significantly alter the disease course in young children with ...

RAHWAY, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or ...

RAHWAY, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in ...

Prednisone is a versatile medication — but it has a few potential side effects. Does prednisone cause hair loss? It’s possible, though there’s not much evidence to confirm it. You may have been ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IPATential150 study met its co-primary endpoint of ...